TLX101-CDx Given Complete Response Letter for Glioma Imaging
The FDA granted a complete response letter with no safety concerns for the new drug application for TLX101-CDx’s use in glioma imaging.
Eftilagimod Alfa/Pembrolizumab May Improve OS in HNSCC With CPS < 1
New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head and neck squamous cell carcinoma.
Lurbinectedin Plus Pembrolizumab May Yield Activity in Relapsed SCLC
Early-phase LUPER trial results suggest the lurbinectedin/pembrolizumab combination may benefit patients with relapsed small cell lung cancer.
First-Line Adagrasib Active in STK11/KRAS G12C–Mutated NSCLC
Adagrasib shows early signs of activity and tolerability in patients with STK11/KRAS G12C–mutated non–small cell lung cancer.
KN026 Combo Boosts PFS in Pretreated HER2+ Gastric/GEJ Cancer
KN026 plus chemotherapy improved PFS in patients with previously treated HER2-positive advanced gastric or GEJ cancer.
Daratumumab Combo Maintains Benefit in Transplant-Ineligible NDMM
Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with transplant-ineligible newly diagnosed multiple myeloma.
A Snapshot of April FDA Approvals in Oncology for Nurses and APPs
Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.
Cretostimogene Grenadenorepvec Yields Durable Response in NMIBC
Cretostimogene grenadenorepvec showed complete response across subgroups in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer.
INX-315 Receives FDA Fast Track Status for CCNE1-Amplified Ovarian Cancer
The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ovarian cancer.
Opinion: Targeted Therapy Plus Immunotherapy Is Promising for ATC
Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive cancer type.
Ready-to-Dilute Thiotepa Approved for Breast and Ovarian Adenocarcinomas
A ready-to-dilute formulation of thiotepa has been approved by the FDA for use in breast and ovarian cancers.
Zanubrutinib Shows Potential Efficacy Edge in High-Risk R/R CLL, Analysis Finds
A network meta-analysis suggests zanubrutinib may offer improved efficacy over other BTK inhibitors for patients with high-risk relapsed/refractory CLL.
Opinion: Increasing Support and Awareness for AYAs With Cancer
AYA Cancer Awareness Month offers an opportunity for nurses to go further in supporting AYAs with cancer.
FDA Declines Breakthrough Status, Halts Itolizumab’s Path Forward in Acute GVHD
The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.
As-Expected Ruxolitinib Starting Dose Outperforms Lower Dosage in Myelofibrosis
Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment reduced daily dosages over 12 months.
Breakthrough Designation Granted to BCB-276 for Pediatric DIPG
Findings from the phase 1 BrainChild-03 trial support breakthrough designation for BCB-276 for pediatric diffuse intrinsic pontine glioma.
FDA Approves 2 Indications for Penpulimab-kcqx in Non-Keratinizing NPC
The FDA approved penpulimab-kcqx combination and monotherapy for non-keratinizing nasopharyngeal carcinoma.
Cancer Mortality Decreased Over 20 Years Despite COVID-19 Pandemic
From 2018 to 2022, cancer mortality dropped across race and ethnicity.
T-DXd Plus Pertuzumab Improves PFS Over THP in HER2+ Metastatic Breast Cancer
Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma
Acupuncture Use in BC Predicted by Social Determinants of Health
Variability Found in PROs, Gene Expression During AML Induction Chemo
Gene expression in peripheral blood as well as patient-reported outcomes differed for those with acute myeloid leukemia undergoing induction chemotherapy.
Blinatumomab-Linked ICANS Cases Higher Than Previously Reported
Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.
Daratumumab Decreased Progression Risk in High-Risk Smoldering MM
Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.
Risk Factors Determine Symptom Burden Profiles by Age Group
Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with cancer.
Study Findings Support D-VRd for Transplant-Ineligible or -Deferred MM
Data from the CEPHEUS trial support the use of D-VRd in patients with transplant-ineligible or -deferred multiple myeloma who can tolerate bortezomib.
Q&A: Prioritizing QOL Important to Treating HR+, HER2- Metastatic Breast Cancer
When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the prioritization of quality of life.
Real-World Data Shows Apalutamide Increases 24-Month OS in mCSPC
Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.
Patient-Centered Communication Drives Supportive Care Needs in Incurable Cancer
The PRECURSOR intervention appeared feasible/acceptable, suggesting a need for patient-centered conversation in incurable gynecologic cancer treatment.
Nurse-Led Sessions Enhance Supportive Care for Patients on Clinical Trials
Sessions addressing supportive care needs for patients with cancer on early phase clinical trials appeared feasible and acceptable in a prospective study.
Mosunetuzumab/Polatuzumab Vedotin Triples PFS in LBCL
Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
